Document is current

Article History

Received: 18 April 2021

Accepted: 23 December 2021

First Online: 31 January 2022

Declarations

:

: TIGER has obtained a favourable opinion from the Cambridge East Research Ethics Committee REC (20/EE/0293), covering all sites in the UK. Additional REC and Institutional Review Board approvals will be sought to cover new sites as they join TIGER in continental Europe. A copy of the ethical approval has been included in Appendix .

: A trial-specific patient informed consent form (ICF) will be used and has been included in the supplementary materials (Appendix ).

: TJ has no conflicts of interests in relation to the IMP under evaluation, or SMH. His employer has received site payments from Bayer for participants enrolled on commercial clinical trials of aflibercept. He serves as a consultant for Opthea, a company investigating a novel treatment for wet AMD. His employer has received payments for trials of other novel and licensed treatments for wet AMD, and he has received research grants from commercial organisations for treatments of wet AMD. RD and CNL’s employer has received payments for trials of novel and licensed treatments for wet AMD, including commercial trials of Eylea. CB’s post is part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London; the views she expresses are her own and not necessarily those of the NIHR or the Department of Health and Social Care. JvM was on the Board of Euretina when it commissioned Fight for Sight to run the call for funding but left the Board in 2019 before the grant was awarded and was not an applicant on the bid.